Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Capital Expenditures (2016 - 2025)

Mimedx's Capital Expenditures history spans 13 years, with the latest figure at $285000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 8.37% year-over-year to $285000.0; the TTM value through Dec 2025 reached $911000.0, up 109.91%, while the annual FY2025 figure was $1.0 million, 38.62% down from the prior year.
  • Capital Expenditures for Q4 2025 was $285000.0 at Mimedx, up from $192000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $667000.0 in Q4 2022 and bottomed at $118000.0 in Q1 2022.
  • The 3-year median for Capital Expenditures is $274000.0 (2024), against an average of $303125.0.
  • The largest YoY upside for Capital Expenditures was 12.28% in 2025 against a maximum downside of 8.37% in 2025.
  • A 3-year view of Capital Expenditures shows it stood at $667000.0 in 2022, then crashed by 60.57% to $263000.0 in 2024, then grew by 8.37% to $285000.0 in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Capital Expenditures are $285000.0 (Q4 2025), $192000.0 (Q3 2025), and $263000.0 (Q4 2024).